Belluscura sets date for key fundraising meeting

Published 12/02/2025, 08:06
Belluscura sets date for key fundraising meeting

LONDON - Belluscura PLC (AIM: BELL), a UK-based medical device company, has announced that it will hold a General Meeting at the offices of Dowgate Capital Limited in London at 11:00 a.m. on February 28, 2025. The purpose of the meeting is to discuss the details of a recently proposed fundraising initiative and to vote on resolutions necessary for its completion.

The fundraising, previously mentioned in announcements on February 6, 7, and 11, 2025, involves the issuance of new ordinary shares. These shares are intended to be admitted to trading on the AIM market of the London Stock Exchange (LON:LSEG). The company has confirmed that the WRAP Retail Offer Shares are expected to be issued on or around March 4, 2025, subject to shareholder approval of the resolutions. This will be followed by the issuance of 56,534,389 VCT/EIS Placing Shares. Additionally, 109,616,986 Conditional Placing Shares are anticipated to be issued on or around March 5, 2025, also contingent upon the passing of the resolutions.

Shareholders received a circular on February 11, 2025, which included a Notice of General Meeting and detailed information about the fundraising initiative. Belluscura has also made the circular available on its website for public viewing.

The company has outlined a timetable for the principal events associated with the fundraising. This includes the crediting of shares in uncertificated form to CREST accounts and the posting of share certificates for the new ordinary shares by the registrar, expected to occur within 14 days of each respective admission.

This announcement is based on a press release statement and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). Upon the publication of this announcement via a Regulatory Information Service, such inside information is now considered to be in the public domain.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.